View in EDS PDF Full Text

DOMENICA study (GINECO-EN105b/ENGO-Ten13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1).

Saved in:
Bibliographic Details
Title: DOMENICA study (GINECO-EN105b/ENGO-Ten13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1).
Authors: Chel Hun Choi1 huna0@naver.com, Ray-Coquard, Isabelle2, Rubio, Maria Jesus3, Paoletti, Xavier4, Hudson, Emma5, Lorusso, Domenica6, Hasler-Strub, Ursula7, Vardar, Mehmet Ali8, Lheureux, Stéphanie9, Van Gorp, Toon10, Shao Peng Tan, David11, Trillsch, Fabian12, Eberst, Lauriane13, Lescure, Céline14, Hardy-Bessard, Anne-Claire15, Chaix, Marie16, Byoung-Gie Kim1, JaeWeon Kim17, JeongYeol Park18, Jung-Yun Lee19
Source: Journal of Gynecologic Oncology. 2024 Supplement, Vol. 35, p19-20. 2p.
Database: Academic Search Ultimate
Description
ISSN:20050380
DOI:10.3802/jgo.2024.35.S2.P1